PRESS RELEASE
News
-
-
PRESS RELEASE
GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
GENFIT highlights long-term commercial opportunity for its MASH Diagnostics Technology. The technology aims to identify patients with 'at-risk MASH' through non-invasive blood-based testing, creating potential for significant revenue streams -
PRESS RELEASE
Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report
Antin Infrastructure Partners releases Half-Year 2026 Financial Report, available on their website. Firm focuses on energy, transport, and digital infrastructure investments -
-
PRESS RELEASE
DocMorris launches private placement of approx. CHF 100 million Convertible Bonds due 2031 to finance early repurchase of Convertible Bonds 2028
DocMorris AG launches CHF 100 million Convertible Bonds private placement to finance early repurchase of Convertible Bonds 2028, optimizing balance sheet and funding costs -
PRESS RELEASE
BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028
BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028 -
PRESS RELEASE
Medacta Group SA: Medacta Group SA reports above-market revenue growth of 9.7% in constant currency1 with a robust adjusted EBITDA margin of 27.8% in c.c.1 in H1 2026
Medacta Group SA reports above-market revenue growth of 9.7% in constant currency with a robust adjusted EBITDA margin of 27.8% in H1 2026. The company attributes growth to innovation and geographical expansion -
-
-
